Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4 ‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial

ConclusionsThe sustained PFS benefit and long ‐term safety of ELd at 4 years, similar to those observed at 2 and 3 years, support ELd as a valuable therapeutic option for the long‐term treatment of patients with RRMM.

Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Meletios A. Dimopoulos, Sagar Lonial, Keith A. Betts, Clara Chen, Miriam L. Zichlin, Alexander Brun, James E. Signorovitch, Dinara Makenbaeva, Sabeen Mekan, Oumar Sy, Katja Weisel, Paul G. Richardson Tags: Original Article Source Type: research